Predict your next investment

HEALTHCARE | Biotechnology
keelpharmaceuticals.com

See what CB Insights has to offer

Stage

Angel - II | Dead

Total Raised

$5.75M

Last Raised

$2.57M

About Keel Pharmaceuticals

Developer of therapies to treat the causes of autoimmune disease, including type 1 diabetes and other autoimmune diseases. The company's technology is based on the identification of specific protein processing and signaling defects in the autoreactive lymphocytes that cause autoimmune disease. The identification of these defects has yielded a approach to the treatment of autoimmunity based on selective destruction of lymphocytes responsible for autoimmune reactions. [Keywords: lupus, scleroderma]

Keel Pharmaceuticals Headquarter Location

215 First Street Suite 104

Cambridge, Massachusetts, 02142,

United States

(617)225-0834

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Keel Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Keel Pharmaceuticals is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,734 items

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.